# Why Does Google Ads Reject Peptide Advertising?

Reviewed November 9, 2026 · By Michael Borgia, MedScale Health

## Short answer

As of November 2026, Google prohibits promoting unapproved substances and restricts prescription drug promotion to certified advertisers, and most telehealth peptides fall into the first group rather than the second. MedScale Health, a paid ads agency for US telehealth brands and clinics, runs a consult-only paid structure for peptide clinics that never names a compound, because certification does not lift the prohibition. Peptide brands often pursue certification expecting it to open the category, when certification solves a different problem.

## Which Google peptide restriction can certification fix?

Google's healthcare policies contain a restriction and a prohibition, and confusing them wastes months. MedScale works with telehealth brands and clinics, and confusing the two is the most common misdiagnosis in the peptide category.

- Prescription medication is restricted, and the remedy is advertiser certification.
- Unapproved pharmaceuticals and supplements are prohibited, and there is no certification that resolves it.

Peptide brands frequently pursue the first remedy for the second problem. Certification is granted or refused on the basis of the business, and even when granted it does not permit advertising a substance the policy prohibits outright.

## Why does Google treat most peptides as unapproved substances?

Google's unapproved substances policy says Google doesn't allow the promotion of certain products, regardless of any claims of legality. It covers the items on Google's non-exhaustive list of unapproved pharmaceuticals and supplements and non-government-approved products marketed in a way that implies they are safe or effective. Many peptides sold through telehealth are not approved for human therapeutic use, which places them there rather than in the restricted-but-permitted group that certification addresses.

BPC-157 shows the pattern. It is not FDA-approved; FDA's bulk substances page, current April 22, 2026, lists it as nominated but withdrawn from Category 2; and an FDA advisory committee's July 2026 vote to recommend it for the 503A bulks list is non-binding. Google's call is a determination about the substance, not about the advertiser. A well-run, properly licensed telehealth business advertising a prohibited substance is still advertising a prohibited substance, so MedScale checks a substance's status before planning any peptide search campaign.

On October 30, 2026, HHS said it does not intend to take enforcement action against 503A pharmacies and physicians compounding BPC-157 under set conditions. That is enforcement discretion, not FDA approval. Google's unapproved substances policy, checked November 3, 2026, still bars products "regardless of any claims of legality," including "Products that have been subject to any government or regulatory action or warning," and still tells advertisers to "refer to LegitScript" for the substances it monitors. MedScale checks that page before any peptide search campaign.

## Can peptide clinics reach peptide searches on Google?

Only part of the demand. The frustration in this category is real, because peptide search demand is substantial and visibly unserved. Brands can see the volume in keyword tools and reasonably conclude there must be a way to capture it.

The reachable portion is narrower than the total. [Queries for a clinic or a consultation](https://medscale.health/answers/marketing-peptides-without-paid-social) can be bought when the consult is genuinely the offer and the page reflects it; queries with direct purchase intent for a prohibited substance generally cannot. Informational queries belong to organic search, which is the brand's job or a content partner's, or MedScale's when the brand hires it for SEO and AEO. MedScale bids only on the clinic and consult queries.

## What happens if a peptide brand tries to get around Google's policy?

Attempting to route around the prohibition, whether through euphemism, redirect pages, or separating the ad from the product page, tends to move the problem from the healthcare policies into misrepresentation or circumvention. Circumvention is a worse position: [Google's circumventing systems policy suspends accounts](https://medscale.health/answers/google-ads-account-suspended-telehealth) on detection, without prior warning, and says the advertiser will not be allowed to advertise with Google Ads again. MedScale runs none of these workarounds for any client.

## Is LegitScript certification worth it for a peptide brand?

Only when the brand also sells something advertisable. A recurring pattern in this category is a brand spending a quarter assembling a certification application, obtaining it, and finding that nothing changes. The application succeeded because the business is legitimate. The ads still fail because the substance is prohibited.

The diagnostic that avoids a wasted quarter is simple and rarely run: establish which policy the disapprovals actually cite before deciding on a remedy. A disapproval citing unapproved substances and one citing an uncertified advertiser look similar in the interface and have entirely different solutions.

MedScale runs that check first for exactly this reason. [Certification is worth pursuing where the brand also operates advertisable categories](https://medscale.health/answers/is-legitscript-certification-worth-it), but pursuing it to open a prohibited substance is a quarter spent on the wrong problem.

Advertising the peptide can also put the certification itself at risk. LegitScript's September 22, 2026 post says a certified business that offers, promotes or advertises a peptide not permissible under current FDA rules, naming BPC-157, TB-500, [retatrutide and cagrilintide](https://medscale.health/answers/can-you-advertise-retatrutide), violates its standards, including through a partner that prescribes or dispenses it, and that content encouraging use of an unapproved drug is impermissible even if the business does not sell it.

On November 2, 2026, LegitScript changed this for six peptides: offering BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c in a way that meets HHS's October 30 policy "should not, by itself, prevent a merchant from achieving certification." Retatrutide and cagrilintide are not covered, and LegitScript says ad platforms set their own policies, "which may differ from LegitScript's requirements."

## How does MedScale run Google Ads for peptide clinics?

MedScale approaches peptide search demand with [a consult-only paid structure](https://medscale.health/telehealth/peptides).

- Search campaigns on clinic and consultation intent, with no compound named in keywords, ad text or on the landing page.
- A landing page that sells the visit, the clinician and the lab work, with any peptide discussed only by the prescriber after the consult.
- Adjacent approved categories where paid can run, with peptides positioned inside an existing patient relationship.
- Organic content for the informational queries, [written by MedScale as part of its SEO and AEO work](https://medscale.health/services/seo) or by the brand's content partner.

A consult-only structure captures less than the total demand. It is the version that does not put the rest of the advertising account at risk. MedScale's [free Growth Audit](https://medscale.health/audit) reads a peptide clinic's live Google ads and landing pages against that line and marks anything on the wrong side of it.

## Next step

**Want this mapped to your account?** The Growth Audit reviews your campaigns, pages and tracking against the rules above and gives you a plan in writing.

- [Get a free Growth Audit](https://medscale.health/audit)
- [Google Ads for weight loss clinics](https://medscale.health/clinics/medical-weight-loss/google-ads)
- [GLP-1 marketing agency](https://medscale.health/telehealth/glp-1-weight-loss)

## FAQ

**Will LegitScript certification let me advertise peptides on Google?**

No, not for a substance in the prohibited category. Certification addresses the restriction on promoting prescription medication, not the prohibition on unapproved pharmaceuticals. Where a substance sits in the prohibited category, certification does not open it, which is why brands pursuing it for that purpose are often disappointed.

**Can I advertise a peptide consultation rather than the peptide?**

Sometimes, provided the consultation is genuinely the offer and the destination page reflects that rather than functioning as a product page. Google reviews the landing page as part of the ad, so the distinction has to be real rather than presentational.

**Why do competitors appear to run peptide ads on Google?**

Because enforcement is not instantaneous or uniform, and ads that are live have not necessarily been reviewed. Treating a competitor's current activity as evidence of compliance means adopting risk that may already be accumulating against their account.

**Can I rank organically for peptide terms instead?**

Yes. Organic content is not subject to advertising policy and can reach informational peptide queries, subject to the usual rules on health claims. It is the brand's job or a content partner's, or MedScale's when the brand hires it for SEO and AEO. MedScale runs the paid side, where the consult-only structure is the realistic route.

## Sources

- [Google Ads policy: Healthcare and medicines](https://support.google.com/adspolicy/answer/176031?hl=en) (checked October 5, 2026)
- [Google Ads policy: Unapproved substances](https://support.google.com/adspolicy/answer/15595718?hl=en) (checked October 5, 2026)
- [Google Ads policy: Prescription drug services](https://support.google.com/adspolicy/answer/15598647?hl=en) (checked October 5, 2026)
- [Google Ads policy: Circumventing systems](https://support.google.com/adspolicy/answer/15938075?hl=en) (checked October 5, 2026)
- [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of Apr 22, 2026)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) (checked October 5, 2026)
- [LegitScript (Sep 22, 2026): The Peptide Boom, why so many popular products are still off-limits](https://www.legitscript.com/healthcare/the-peptide-boom-why-so-many-popular-products-are-still-off-limits/) (checked October 12, 2026)
- [Federal Register 2026-22192 (Oct 30, 2026): HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (RIN 0910-ZD94)](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances) (checked November 3, 2026)
- [HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) (checked November 3, 2026)
- [LegitScript (Nov 2, 2026): HHS's Peptide Compounding Policy, what healthcare businesses need to know](https://www.legitscript.com/healthcare/hhs-peptide-compounding-policy-what-healthcare-businesses-need-to-know/) (checked November 3, 2026)

## Related

- [Can You Advertise Peptides on Meta?](https://medscale.health/answers/can-you-advertise-peptides-on-meta)
- [Why Are Your Google Ads Disapproved for Telehealth, and How Do You Fix It?](https://medscale.health/answers/why-google-rejects-telehealth-ads)
- [Can You Advertise BPC-157, and What Does the FDA Status Mean?](https://medscale.health/answers/bpc-157-fda-bulk-substances-list)

Canonical page: https://medscale.health/answers/peptides-and-google-ads